Brandenburg Klaus, Schürholz Tobias
Klaus Brandenburg, Forschungszentrum Borstel, Leibniz-Zentrum für Medizin und Biowissenschaften, D-23845 Borstel, Germany.
World J Biol Chem. 2015 Aug 26;6(3):71-7. doi: 10.4331/wjbc.v6.i3.71.
The lack of newly developed antibiotics, together with the increase in multi-resistance of relevant pathogenic bacteria in the last decades, represents an alarming signal for human health care worldwide. The number of severely infected persons increases not only in developing but also in highly industrialized countries. This relates in first line to the most severe form of a bacterial infection, sepsis and the septic shock syndrome, with high mortality on critical care units. No particular anti-sepsis drug is available, and the therapy with conventional antibiotics more and more fails to provide a survival benefit. Due to the fact that the pharmaceutical industry has withdrawn to a high degree from the development of anti-infectious agents, a huge challenge for health care is approaching in the 21(st) century. In this article, these problems are outlined and possible alternatives are presented which may be helpful to solve the problem.
在过去几十年中，新开发抗生素的缺乏，加上相关病原菌多重耐药性的增加，对全球人类医疗保健而言是一个警示信号。不仅在发展中国家，而且在高度工业化国家，严重感染患者的数量都在增加。这首先与细菌感染最严重的形式——败血症和脓毒性休克综合征有关，在重症监护病房死亡率很高。目前没有特效的抗败血症药物，使用传统抗生素进行治疗越来越无法带来生存获益。由于制药行业已在很大程度上退出抗感染药物的研发，21世纪医疗保健将面临巨大挑战。本文概述了这些问题，并提出了可能有助于解决该问题的替代方案。
